ArticleCore evidence2019
Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy.
Article in Core evidence, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study.Journal of bone and mineral metabolism · 2021Trial
- Update on Glucocorticoid-Induced Osteoporosis: Emerging Therapeutic Strategies.Endocrinology and metabolism (Seoul, Korea) · 2026Review
- Clinical Practice Patterns in Bone Health Assessment and Management in Endogenous Cushing's Syndrome.Clinical endocrinology · 2026Article
- Glucocorticoid-Induced Osteoporosis: Pathogenesis, the Impact of Different Administration Routes on Bone Mineral Density, and Fracture Risk and Treatment Options-A Narrative Review.Journal of clinical medicine · 2026Review
- Revolutionizing osteoporosis management: the emerging role of immunotherapeutic and next-generation therapies.Inflammopharmacology · 2025Review
- Review
- Geraniin Promotes Osteoblast Proliferation, Bone Formation, and Autophagy by Regulating the PI3K/Akt/mTOR Cascade to Improve Glucocorticoid-Induced Osteoporosis.Calcified tissue international · 2025Article
- Denosumab in the Management of Glucocorticoid-Induced Osteoporosis: Long-Term Efficacy and Secondary Fracture Outcomes.Journal of clinical medicine · 2025Article
- Characterization and preparation of food-derived peptides on improving osteoporosis: A review.Food chemistry: X · 2024Article
- Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?Endocrine reviews · 2023Review
- Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.British medical bulletin · 2022Article
- [Glucocorticoid-induced osteoporosis-Focus treatment (part 2)].Zeitschrift fur Rheumatologie · 2022Article
- Bone Health in Idiopathic Inflammatory Myopathies: Diagnosis and Management.Current rheumatology reports · 2021Review
- Update on Glucocorticoid Induced Osteoporosis.Endocrinology and metabolism (Seoul, Korea) · 2021Article
- Segmental Bone Reconstruction by Octacalcium Phosphate Collagen Composites with Teriparatide.Tissue engineering. Part A · 2021Article
- Therapies for Preventing Bone Loss with Glucocorticoid Treatment.Current osteoporosis reports · 2021Review
- Tanshinol Alleviates Microcirculation Disturbance and Impaired Bone Formation by Attenuating TXNIP Signaling in GIO Rats.Frontiers in pharmacology · 2021Article
- CK2.3, a Mimetic Peptide of the BMP Type I Receptor, Increases Activity in Osteoblasts over BMP2.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGlucocorticoid-induced osteoporosis is an underrecognized complication of chronic glucocorticoid therapy characterized by a decrease in new bone formation. Anabolic therapies, such as teriparatide, a recombinant human parathyroid hormone, combat the disease by promoting new bone growth.
aimsThis article outlines the pathophysiology of glucocorticoid-induced osteoporosis and details the evidence of efficacy, safety, and patterns of use of teriparatide and other future anabolic therapies. EVIDENCE REVIEW: In multiple clinical trials, teriparatide has been shown to significantly increase lumbar spine bone mineral density (BMD) in patients with glucocorticoid-induced osteoporosis when compared with placebo, alendronate, and risedronate. When compared with alendronate, significantly fewer vertebral fractures were noted in the teriparatide group. Adverse effects noted in clinical trials include nausea, insomnia, flushing, myalgias, and mild hypercalcemia/hyperuricemia. Early studies in rats noted an increased incidence of osteosarcoma; however, an increased rate beyond levels seen in general populations has not been noted in human studies or with long-term pharmacovigilance. Abaloparatide and romosozumab are newer anabolic therapies that have shown some benefit in postmenopausal osteoporosis but have not yet been studied in the chronic glucocorticoid population. PLACE IN THERAPY: Major specialty organizations continue to recommend bisphosphonates as first-line therapy in glucocorticoid-induced osteoporosis due to the proven benefit and relative affordability. However, the use of anabolics shows promise to improve outcomes by increasing BMD and reducing fracture-associated morbidity and mortality and has a role for selected populations at high fracture risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.